Editorial Comment: Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer

被引：0
|
作者：
Lott, Felipe [1 ]
机构：
[1] Inst Nacl Canc INCA, Rio De Janeiro, RJ, Brazil
来源：
INTERNATIONAL BRAZ J UROL | 2021年 / 47卷 / 01期
关键词：
D O I：
10.1590/S1677-5538.IBJU.2021.01.08
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [1] Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
    Hoyle, Alex P.
    Ali, Adnan
    James, Nicholas D.
    Cook, Adrian
    Parker, Christopher C.
    de Bono, Johann S.
    Attard, Gerhardt
    Chowdhury, Simon
    Cross, William R.
    Dearnaley, David P.
    Brawley, Christopher D.
    Gilson, Clare
    Ingleby, Fiona
    Gillessen, Silke
    Aebersold, Daniel M.
    Jones, Rob J.
    Matheson, David
    Millman, Robin
    Mason, Malcolm D.
    Ritchie, Alastair W. S.
    Russell, Martin
    Douis, Hassan
    Parmar, Mahesh K. B.
    Sydes, Matthew R.
    Clarke, Noel W.
    EUROPEAN UROLOGY, 2019, 76 (06) : 719 - 728
  • [2] Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now
    McKay, Rana R.
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 45 : 41 - 43
  • [3] Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 195 (01): : 94 - 94
  • [4] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [5] Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply
    Borque-Fernando, A.
    Calleja-Hernandez, M. A.
    Cozar-Olmo, J. M.
    Gomez-Iturriaga, A.
    Perez-Fentes, D. A.
    Puente-Vazquez, J.
    Rodrigo-Aliaga, M.
    Unda, M.
    Alvarez-Ossorio, J. L.
    ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (06): : 392 - 393
  • [6] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
  • [7] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
    Takashi Ueda
    Kazutoshi Fujita
    Mitsuhisa Nishimoto
    Takumi Shiraishi
    Masatsugu Miyashita
    Naruhiro Kayukawa
    Yuichi Nakamura
    Satoshi Sako
    Ryota Ogura
    Atsuko Fujihara
    Takafumi Minami
    Fumiya Hongo
    Koji Okihara
    Kazuhiro Yoshimura
    Hirotsugu Uemura
    Osamu Ukimura
    World Journal of Urology, 2022, 40 : 2939 - 2946
  • [8] Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
    Miller, Kurt
    AKTUELLE UROLOGIE, 2019, 50 (06) : 625 - 628
  • [9] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
    Ueda, Takashi
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Shiraishi, Takumi
    Miyashita, Masatsugu
    Kayukawa, Naruhiro
    Nakamura, Yuichi
    Sako, Satoshi
    Ogura, Ryota
    Fujihara, Atsuko
    Minami, Takafumi
    Hongo, Fumiya
    Okihara, Koji
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    Ukimura, Osamu
    WORLD JOURNAL OF UROLOGY, 2022, 40 (12) : 2939 - 2946
  • [10] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
12345